Literature DB >> 6186329

Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction.

P R Rossi, S Yusuf, D Ramsdale, L Furze, P Sleight.   

Abstract

The effect of intravenous atenolol on ventricular arrhythmias in acute myocardial infarction was assessed in 182 patients admitted within 12 hours of the onset of chest pain. Ninety-five patients were randomised to receive 5 mg intravenous atenolol followed immediately by 50 mg by mouth and 50 mg 12 hours later, then 100 mg daily for 10 days; 87 patients served as controls. The treated patients had significantly fewer ventricular extrasystoles; 58 control patients (67%) had R-on-T extrasystoles compared with only 25 treated patients (26%) (2p less than 0.0001); repetitive ventricular arrhythmias were detected in 64 control patients (74%) and 55 treated patients (58%) (2p less than 0.05). Heart rate was significantly reduced from 77 +/- 1 beats/min at entry to 65 +/- 1 beats/min (2p less than 0.001) in the first hour after intravenous atenolol, and in addition the rate was significantly different from that in the control group. There was no difference in the incidence of heart failure, but fewer patients in the treated group received other antiarrhythmic agents or digoxin. These results show that early intravenous atenolol prevents ventricular arrhythmias in suspected acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186329      PMCID: PMC1546543          DOI: 10.1136/bmj.286.6364.506

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  37 in total

1.  Absence of prophylactic effect of propranolol in myocardial infarction.

Authors:  J Clausen; M Felsby; F S Jorgensen; B L Nielsen; J Roin; B Strange
Journal:  Lancet       Date:  1966-10-29       Impact factor: 79.321

2.  Use of alprenolol in acute cardiac arrhythmias.

Authors:  L Lemberg; A G Arcebal; A Castellanos; D Slavin
Journal:  Am J Cardiol       Date:  1972-07-11       Impact factor: 2.778

3.  Free noradrenaline and adrenaline excretion in relation to the development of cardiac arrhythmias and heart-failure in patients with acute myocardial infarction.

Authors:  D E Jewitt; D Reid; M Thomas; C J Mercer; C Valori; J P Shillingford
Journal:  Lancet       Date:  1969-03-29       Impact factor: 79.321

4.  Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction.

Authors:  M F Oliver; V A Kurien; T W Greenwood
Journal:  Lancet       Date:  1968-04-06       Impact factor: 79.321

5.  Serum-free-fatty-acids and their relation to complications after acute myocardial infarction.

Authors:  H L Rutenberg; J C Pamintuan; L A Soloff
Journal:  Lancet       Date:  1969-09-13       Impact factor: 79.321

6.  Practolol in the treatment of cardiac dysrhythmias due to acute myocardial infarction.

Authors:  D E Jewitt; C J Mercer; J P Shillingford
Journal:  Lancet       Date:  1969-08-02       Impact factor: 79.321

7.  Plasma-catecholamines after cardiac infarction.

Authors:  L McDonald; C Baker; C Bray; A McDonald; N Restieaux
Journal:  Lancet       Date:  1969-11-15       Impact factor: 79.321

8.  Trial of propranolol in acute myocardial infarction.

Authors:  R M Norris; D E Caughey; P J Scott
Journal:  Br Med J       Date:  1968-05-18

9.  Ventricular tachyarrhythmias and lignocaine prophylaxis in acute myocardial infarction. A clinical and therapeutic study.

Authors:  L Mogensen
Journal:  Acta Med Scand Suppl       Date:  1970

10.  Use of oxprenolol in cardiac arrhythmias associated with acute myocardial ischaemia.

Authors:  G Sandler; A C Pistevos
Journal:  Br Med J       Date:  1971-01-30
View more
  12 in total

1.  Treatment of hypertension in older adults.

Authors:  J M Cruickshank
Journal:  BMJ       Date:  1992-04-11

Review 2.  Choosing the right beta-blocker. A guide to selection.

Authors:  J R Hampton
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 3.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

4.  Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.

Authors:  G T Tucker; N D Bax; M S Lennard; S Al-Asady; H S Bharaj; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

5.  Limitation of myocardial infarct size. Present status.

Authors:  S Yusuf; P Sleight
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

Review 6.  Secondary prevention after myocardial infarction: effects of beta blocking agents and calcium antagonists.

Authors:  P Depelchin; J Sobolski; M Jottrand; C Flament
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

7.  Comparative haemodynamic dose-response effects of intravenous propranolol and pindolol in patients with coronary heart disease.

Authors:  B Silke; G I Nelson; R C Ahuja; R C Okoli; S H Taylor
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Combined receptor intervention and myocardial infarction.

Authors:  D A Chamberlain; R Vincent
Journal:  Drugs       Date:  1984       Impact factor: 9.546

9.  Intramuscular atenolol and levetiracetam reduce mortality in a rat model of paraoxon-induced status epilepticus.

Authors:  Laxmikant S Deshpande; Robert E Blair; Matthew Halquist; Leon Kosmider; Robert J DeLorenzo
Journal:  Ann N Y Acad Sci       Date:  2020-09-22       Impact factor: 5.691

Review 10.  Cardiovascular benefits of antihypertensive therapy postacute myocardial infarction. Therapeutic considerations.

Authors:  P Sleight
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.